What happened

CVS Health beat big on Q2 and raised its full-year outlook — and the stock still fell. Shares opened down as much as ~10% and were off about 6% near midday, around $98 (Investing.com, Benzinga). Adjusted profit landed at $2.58 a share versus roughly $1.86 expected, and revenue rose 7.3% to $106.1 billion, clearing the ~$100–101 billion Street estimate. Adjusted operating income jumped 35% to $5.16 billion, with growth in every segment. On paper, close to flawless.

Why a beat-and-raise still sank it

Two reasons, and it's worth keeping them separate. First, the stock had already run up roughly 60% since the end of March (Benzinga), so a strong quarter was largely in the price and holders cashed some out. Second, and more specific: on the earnings call management pointed at 2027. CFO Brian Newman said CVS expects membership declines in Caremark — its pharmacy-benefit-manager (PBM) arm — next year, and that its 340B drug-discount business will stay a headwind. A PBM is the middleman that negotiates drug prices for insurers and employers; Caremark is one of three that route most US prescriptions. Fewer members there dents a high-margin engine, so the market looked past a great quarter and sold the cautious 2027 setup.

Is it expensive?

Here's the twist. On trailing earnings CVS looks pricey — a P/E near 45 (StockAnalysis) — because last year's profits were dented by Aetna's high medical costs. But on forward earnings, using the guidance it just raised, the P/E drops to roughly 13–14. So the market is paying a low multiple for a recovery it now believes in. For scale, UnitedHealth trades near 32x trailing earnings. CVS's market cap sits around $125 billion after today's slide. Cheap on forward numbers — provided the recovery actually holds.

The business

CVS isn't just the drugstore on the corner. It's three businesses bolted together: Aetna health insurance (Health Care Benefits, ~$37.5B revenue this quarter), Caremark the PBM (Health Services, ~$51.8B), and the retail pharmacies and stores (Pharmacy & Consumer Wellness, ~$33.8B, with prescriptions filled up 4.3% to 457 million). Today's worry is one slice — Caremark — not the whole company. The insurance side actually improved: Aetna's medical benefit ratio (the share of premiums paid back out as claims) fell to 87.4% from 89.9% a year ago, so it's keeping more of each premium dollar.

Who else it touches

• PBM rivals — Cigna's Express Scripts and UnitedHealth's OptumRx: if Caremark sheds members, they can pick some up. The whole PBM model is already under FTC scrutiny.
• Health insurers — Aetna's better cost ratio is an encouraging read-through for UnitedHealth, Elevance, Humana and Cigna.
• GLP-1 makers — CVS also launched cheaper weight-loss-drug access (a $29 virtual visit; as little as $25/month for eligible insured patients) with Eli Lilly. Wider access helps Lilly and Novo Nordisk move more volume.
• Indian generics — Sun Pharma, Dr Reddy's and Aurobindo feed the US retail-pharmacy channel CVS dominates, so its pharmacy volumes ripple to them.

What to watch

The argument is about 2027, not this quarter. If the Caremark membership loss proves smaller than feared and Aetna's cost recovery keeps going, that low forward multiple can re-rate higher. If the 2027 PBM and 340B erosion runs deeper than management let on, today's drop won't be the last leg down.

As of ~12:45 pm ET, Aug 5, 2026. Sources: Benzinga, CNBC, Investing.com, StockAnalysis. For discussion and education only — not investment advice. Verify before acting.